Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer

Cell Cycle

Volumn 8, Issue 24, 2009, Pages 4155-4167

  Narizhneva, Natalia V ^a   Tararova, Natalia D ^a   Ryabokon, Petro ^a   Shyshynova, Inna ^a   Prokvolit, Anatoly ^b   Komarov, Pavel G ^a   Purmal, Andrei A ^a   Gudkov, Andrei V ^a,b   Gurova, Katerina V ^b  

^a CLEVELAND BIOLABS INC   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Androgen receptor; Castration; Cell death; Prostate cancer; Small molecule

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR TRANSCRIPTION INHIBITOR; ANTINEOPLASTIC AGENT; C 52; MUTANT PROTEIN; PROTEIN INHIBITOR; SMALL INTERFERING RNA; STEROID RECEPTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CASTRATION; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; GENE REPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIGAND BINDING; MOLECULAR LIBRARY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN FUNCTION; TRANSACTIVATION;

EID: 74849083394     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.24.10316     Document Type: Article

References (36)

1. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002; 60:132-8.
2. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8:440-8.
3. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. Androgen receptor downregulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005; 96:251-8.
4. Tararova ND, Narizhneva N, Krivokrisenko V, Gudkov AV, Gurova KV. Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate 2007; 67:1801-15.
5. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002; 62:1008-13.
6. Huggins C. Effect of Orchiectomy and Irradiation on Cancer of the Prostate. Ann Surg 1942; 115:1192-200.
7. Kaliks RA, Del Giglio A. Management of advanced prostate cancer. Rev Assoc Med Bras 2008; 54:178-82.
8. Namiki M, Kitagawa Y, Mizokami A, Koh E. Primary combined androgen blockade in localized disease and its mechanism. Best Pract Res Clin Endocrinol Metab 2008; 22:303-15.
9. Lee JT, Lehmann BD, Terrian DM, Chappell WH, Stivala F, Libra M, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7:1745-62.
10. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation anti-androgen for treatment of advanced prostate cancer. Science 2009; 324:787-90.
11. Amato RJ, Teh BS, Henary H, Khan M, Saxena S. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urol Oncol 2009; 27:165-9.
12. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 2005; 102:6201-6.
13. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33-9.
14. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63:149-53.
15. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998; 152:1-9.
16. Marques RB, Erkens-Schulze S, de Ridder CM, Hermans KG, Waltering K, Visakorpi T, et al. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. Int J Cancer 2005; 117:221-9.
17. Tilley WD, Buchanan G, Hickey TE, Bentel JM. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996; 2:277-85.
18. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancerinitiating cells. Cancer Res 2008; 68:9703-11.
19. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, et al. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62:6606-14.
20. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57:406-12.
21. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61:2892-8.
22. Bramlett KS, Dits NF, Sui X, Jorge MC, Zhu X, Jenster G. Repression of androgen-regulated gene expression by dominant negative androgen receptors. Mol Cell Endocrinol 2001; 183:19-28.
23. Geserick C, Meyer HA, Haendler B. The role of DNA response elements as allosteric modulators of steroid receptor function. Mol Cell Endocrinol 2005; 236:1-7.
24. Tenbaum S, Baniahmad A. Nuclear receptors: structure, function and involvement in disease. Int J Biochem Cell Biol 1997; 29:1325-41.
25. Zhou C, Wu G, Feng Y, Li Q, Su H, Mais DE, et al. Discovery and biological characterization of a novel series of androgen receptor modulators. Br J Pharmacol 2008; 154:440-50.
26. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005; 280:37747-54.
27. Salvati ME, Balog A, Shan W, Wei DD, Pickering D, Attar RM, et al. Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists. Bioorg Med Chem Lett 2005; 15:271-6.
28. Jones JO, Bolton EC, Huang Y, Feau C, Guy RK, Yamamoto KR, et al. Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci USA 2009; 106:7233-8.
29. Gunther JR, Parent AA, Katzenellenbogen JA. Alternative inhibition of androgen receptor signaling: peptidomimetic pyrimidines as direct androgen receptor/coactivator disruptors. ACS Chem Biol 2009; 4:435-40.
30. Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, et al. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem 2009; 52:3597-617.
31. Segnitz B, Gehring U. The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J Biol Chem 1997; 272:18694-701.
32. English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989; 15:233-50.
33. Sengupta S, Wasylyk B. Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Ann N Y Acad Sci 2004; 1024:54-71.
34. Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR. Mol Cell Biol 2003; 23:104-18.
35. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004; 64:1951-8.
36. Singh P, Hallur G, Anchoori RK, Bakare O, Kageyama Y, Khan SR. Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate 2008; 68:1570-81.